Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-136834

Published: 2020

Journal Articles

R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma

Juan Pablo Alderuccio, MD, Sunil Iyer, MD, Isildinha M Reis, PhD, Alvaro J. Alencar, MD, Joseph D. Rosenblatt, MD, Izidore S. Lossos, MD

Blood (2019) 134 (Supplement_1): 3992.

https://doi.org/10.1182/blood-2019-125004

Published: 2019

Journal Articles

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana H Advani, MD, Pauline Brice, MD, Nancy L Bartlett, MD, Joseph D Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A Fanale, MD, Joseph M. Connors, Keenan Fenton, Dirk Huebner, MD, Juan Pinelli, Andrei R. Shustov

Blood (2016) 128 (22): 4144.

https://doi.org/10.1182/blood.V128.22.4144.4144

Published: 2016

Journal Articles

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, Jeffrey Matous, MD, Radhakrishnan Ramchandern, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yinghui Wang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, BCOP, Andrei R. Shustov, MD

Blood (2014) 124 (21): 3095.

https://doi.org/10.1182/blood.V124.21.3095.3095

Published: 2014

Journal Articles

Phase II study of 90 y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma

Jesus C Fabregas, MD, James E. Hoffman, MD, Tulay Koru-Sengul, PhD, Miao Feng, Deborah Goodman, Aldo Serafini, MD, Peter J Hosein, MD, Alexandra Stefanovic, MD, Joseph D. Rosenblatt, MD, Izidore S. Lossos, MD

Blood (2014) 124 (21): 1762.

https://doi.org/10.1182/blood.V124.21.1762.1762

Published: 2014

Journal Articles

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana H. Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2013) 122 (21): 1809.

https://doi.org/10.1182/blood.V122.21.1809.1809

Published: 2013

Journal Articles

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Ajay K. Gopal, MD, Robert Chen, MD, Scott E. Smith, MD, PhD, Stephen M Ansell, M.D.Ph.D., Joseph D Rosenblatt, MD, Kerry J. Savage, MD, MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dirk Huebner, MD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2013) 122 (21): 4382.

https://doi.org/10.1182/blood.V122.21.4382.4382

Published: 2013

Journal Articles

Targeting B-Cell Malignancies With Anti-CD20-Interleukin-21 Fusokine

Shruti Bhatt, MS, Daxing Zhu, MD, Xiaoyu Jiang, PhD, Seung-uon Shin, PhD, John M Timmerman, MD, Joseph D. Rosenblatt, MD, Izidore S Lossos, MD

Blood (2013) 122 (21): 377.

https://doi.org/10.1182/blood.V122.21.377.377

Published: 2013

Journal Articles

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Barbara Pro, MD, Ranjana H. Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, PhD, Jeffrey V. Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD

Blood (2012) 120 (21): 2745.

https://doi.org/10.1182/blood.V120.21.2745.2745

Published: 2012

Journal Articles

Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, Stephen M. Ansell, M.D., Ph.D., Joseph D. Rosenblatt, MD, Kerry J. Savage, MD MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Eric L. Sievers, MD, Anas Younes, MD

Blood (2012) 120 (21): 3689.

https://doi.org/10.1182/blood.V120.21.3689.3689

Published: 2012

Journal Articles

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Blood (2012) 120 (21): 3701.

https://doi.org/10.1182/blood.V120.21.3701.3701

Published: 2012

Journal Articles

Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma

Jose D Sandoval-Sus, MD, Peter J Hosein, MD, Deborah Goodman, BHSC, Alexandra Stefanovic, MD, Joseph D Rosenblatt, MD, Izidore S Lossos, MD

Blood (2012) 120 (21): 1622.

https://doi.org/10.1182/blood.V120.21.1622.1622

Published: 2012

Journal Articles

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

Ranjana H. Advani, MD, Andrei R. Shustov, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, MD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dana A. Kennedy, PharmD, Barbara Pro, MD

Blood (2011) 118 (21): 443.

https://doi.org/10.1182/blood.V118.21.443.443

Published: 2011

Journal Articles

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Tim Illidge, Reda Bouabdallah, MD, Robert W. Chen, MD, Ajay K. Gopal, MD, Craig H. Moskowitz, MD, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, MD, Andrei R. Shustov, MD, Herve Tilly, MD, Tanya Trippett, MD, Laurie E. Grove, PA-C, Ranjana H. Advani, MD

Blood (2011) 118 (21): 3091.

https://doi.org/10.1182/blood.V118.21.3091.3091

Published: 2011

Journal Articles

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Andrei R. Shustov, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, MD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Eric L. Sievers, MD, Dana A. Kennedy, PharmD, Barbara Pro, MD

Blood (2010) 116 (21): 961.

https://doi.org/10.1182/blood.V116.21.961.961

Published: 2010

Journal Articles

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, FACP, Stephen M. Ansell, MD, PhD, Joseph D. Rosenblatt, MD, Richard Klasa, MD, CM, FRCP(C), Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dana A. Kennedy, PharmD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2010) 116 (21): 283.

https://doi.org/10.1182/blood.V116.21.283.283

Published: 2010

Journal Articles

Regulation of TLR Signaling by USP7.

Yaohong Tan, MD, Ph.D, Joseph D. Rosenblatt, MD, Howard J. Federoff, MD, Ph. D, William J. Bowers, Ph.D, Khaled A. Tolba, MD

Blood (2007) 110 (11): 2300.

https://doi.org/10.1182/blood.V110.11.2300.2300

Published: 2007

Journal Articles

HSV ICP0 Inhibits TLR-Mediated NF-κB Response to TLR Signaling.

Khaled A. Tolba, MD, William Bowers, Ph.D, Yaohong Tan, MD, Ph.D, Sandrine Daubeuf, Ph.D, Howard J. Federoff, MD, Ph.D., Joseph D. Rosenblatt, MD

Blood (2006) 108 (11): 5487.

https://doi.org/10.1182/blood.V108.11.5487.5487

Published: 2006

Journal Articles

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Blood (2006) 108 (11): 2718.

https://doi.org/10.1182/blood.V108.11.2718.2718

Published: 2006

Journal Articles

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

Ranjana Advani, MD, Andres Forero-Torres, MD, Richard R. Furman, MD, Joseph D. Rosenblatt, MD, Anas Younes, MD, Brooke Shankles, MA, Kate Harrop, BA, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 695.

https://doi.org/10.1182/blood.V108.11.695.695

Published: 2006

NARROW

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Phase II study of 90 y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Targeting B-Cell Malignancies With Anti-CD20-Interleukin-21 Fusokine

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Regulation of TLR Signaling by USP7.

HSV ICP0 Inhibits TLR-Mediated NF-κB Response to TLR Signaling.

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only